Biohaven .(US:BHVN) Prnewswire·2024-05-29 11:15Core Insights - Biohaven Ltd. has initiated a Phase 1/2 clinical trial for BHV-1510, a novel antibody drug conjugate (ADC) targeting Trophoblast Cell Surface Antigen-2 (Trop-2), which has shown promising preclinical efficacy and safety profiles [1][3][4] - The trial will explore BHV-1510 as a monotherapy and in combination with Regeneron's anti-PD-1 therapy, Libtayo® [1][4] - The advanced forms of epithelial tissue malignancies represent a significant unmet medical need, highlighting the importance of this clinical trial [1] Company Overview - Biohaven is a global clinical-stage biopharmaceutical company focused on developing therapies for a range of diseases, including oncology [1][7] - The company is advancing a portfolio of differentiated ADCs, leveraging proprietary technologies to enhance therapeutic margins and efficacy [6][7] - Biohaven's ADC technology aims to differentiate from existing market options by utilizing advanced payloads and conjugation methods [5][6] Clinical Trial Details - The Phase 1/2 study is a multicenter, open-label trial targeting advanced or metastatic epithelial cell tumors, consisting of a dose-escalation phase followed by a multicohort expansion phase [2] - The trial is registered under NCT06384807, and additional details can be found on clinical trial registries [2] Collaboration and Development - Biohaven has entered into a clinical supply agreement with Regeneron, where Biohaven will fund the trial while Regeneron provides Libtayo [4] - The collaboration aims to efficiently explore the potential of BHV-1510 in combination with Libtayo across various tumor types [3][4] Technology and Innovation - BHV-1510 is characterized by a homogeneous drug-antibody ratio (DAR) of 4 and utilizes a unique site-specific conjugation methodology, enhancing its stability and efficacy [3][5] - The proprietary MATE™ platform technology focuses on novel conjugation chemistry, which may offer advantages over traditional methods used in the industry [6]